histologically or cytologically confirmed diagnosis of nsclc that carries an alk rearrangement defined as positive using the fda approved vysis alk break apart fish probe kit (abbott molecular inc.) test and scoring algorithm (including positivity criteria) or positive as assessed by the cfda approved immunohistochemistry (ihc) test (ventana medical systems, inc)

age 18 years or older at the time of informed consent.

patients must have stage iiib or iv nsclc at the time of study entry and have had progressive disease during or after crizotinib treatment whether or not previously treated with cytotoxic chemotherapy. if treated with chemotherapy, maximum 2 lines are allowed.

patients with known hypersensitivity to any of the excipients of ldk378

patients with symptomatic central nervous system (cns) metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage cns symptoms

history of carcinomatous meningitis

presence or history of a malignant disease other than nsclc that has been diagnosed and/or required therapy within the past 3 years.

clinically significant, uncontrolled heart disease.